首页> 外文期刊>Journal of International Medical Research >Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator (rt-PA) in Acute Lower Limb Ischaemia
【24h】

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator (rt-PA) in Acute Lower Limb Ischaemia

机译:重组组织纤溶酶原激活剂(rt-PA)静脉溶栓治疗急性下肢缺血

获取原文
           

摘要

For various reasons some patients are unable to undergo intra-arterial thrombolysis for acute limb ischaemia. This interventional case series study prospectively evaluated the effect of thrombolytic treatment with 100 mg recombinant tissue plasminogen activator (rt-PA), administered intravenously, in patients with acute thrombosis of the lower limb arteries and onset of symptoms within 12 h prior to treatment. During a 3-year period (2007 – 2009), 18 of 86 patients satisfied the inclusion criteria and were included in the study (age range 65 – 80 years; 11 women). Complete and partial thrombolysis was observed in eight (44.4%) and six (33.3%) patients, respectively. All patients experienced clinical improvement. There were no amputations during the 36-month follow-up period and no haemorrhagic complications in the first 30 days post-treatment. Five patients died (27.8%) during follow-up from unrelated causes. This small study demonstrated that thrombolytic treatment with intravenous rt-PA in selected patients with acute limb ischaemia is feasible.
机译:由于各种原因,一些患者因急性肢体缺血无法进行动脉内溶栓治疗。这项介入性病例系列研究前瞻性评估了100 mg重组组织纤溶酶原激活剂(rt-PA)静脉溶栓对下肢动脉急性血栓形成并在治疗前12小时内出现症状的患者的溶栓治疗效果。在3年期间(2007年至2009年),有86位患者中的18位满足纳入标准并被纳入研究(年龄范围65至80岁; 11位女性)。分别在八名(44.4%)和六名(33.3%)患者中观察到完全和部分溶栓。所有患者均经历了临床改善。在治疗后的前30天内,在36个月的随访期间没有截肢,也没有出血并发症。随访期间有5例患者死于非相关原因,占27.8%。这项小型研究表明,对于某些急性肢体缺血患者,采用rt-PA静脉溶栓治疗是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号